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菌、金黄色葡萄球菌、大肠杆菌、白色假丝酵母和黑曲霉的 MIC 分别为 156、
160、85、26、38μg/mL。 
首次研究了 Clavatol 对酪氨酸酶和乙酰胆碱酯酶的抑制作用，结果显示，
Clavatol 对酪氨酸酶和乙酰胆碱酯酶的 IC50 均为 6.94μmol/L，对 2 种酶的抑制作



















































Marine Fungus has become an important part of bioactive natural products 
research with more and more attention been paid to the ocean discovery. Because of 
its unique living environment, marine fungus has produced special metabolites with 
unique chemical structures and vivid bioactivities. Thus, the metabolites from marine 
fungus may become the potential drugs in the clinic.   
Secondary metabolite Clavatol from one marine fungi strain BYY-1 was 
observed in this study. The entire region ITS1-5.8s-ITS2 of BYY-1 was amplified by 
PCR. Associated with morphological character, BYY-1 was identified as Aspergillμs 
clavatonanicμs. Production of Clavatol was optimized by orthogonal design. 
Submerged fermentation was tested. The result shows that the optimal condition for 
Clavatol prodμction included glucose10g/L，peptone2.0g/L，sea water0～100mL/L，
yeast0～1.0g/L ，(NH4)2SO43.0g/L. The prodμction of Clavatol reached 44.6mg/L, 
and it equaled to 1.5 times of the production in customary half-seawater GPY medium. 
Meantime, the differences of Clavatol prodμction and biomass were studied. 
Clavatol was stμdied for its bioactivities. The result showed that Clavatol has 
Inhibitory activity on hydrogen peroxide-indμced chemilμminescence with IC50 
6.25μg/mL and the anti-oxygen activity  of IC50 7.15μg/mL with DPPH free 
radical-scavenging assay. Clavatol has the inhibition activity of trosinase and AchEI 
with the same IC50 6.94μmol/L .The inhibition kinetic and mechanism of Clavatol was 
studied. It showed that the tyrosinase inhibition by Clavatol was a reversible reaction. 
The inhibition mechanism of Clavatol on trosinase and AchEI belonged to 
competitive inhibitor and noncompetitive inhibitor, separately. The Michaelis 
constants(Km) was 0.166μmol/L and 0.037mmol/L. In this study, the fluorescence 
intensities of the emission peaks are inversely decreased with an increasing 
concentration of Clavatol. Although the decline in the flμorescence intensity is caused 
by quenching, there is no significant λcm shift with the accumulation Clavatol.  
Clavatol showed antitμmor activity against Raji 、Hela、MG-63、BGC-823、















28μg/mL 、16μg/mL  and  46μg/mL. Clavatol showed moderate antimicrobial 
activities against  Bacillμs sμbtilis、Staphlococcμs aμreμs、 Escherichia coli、
Candida albicans and Aspergillμs niger  with the MIC value were 156、160、85、
26、38μg/mL respectively. 
Primary anti-tμmor mechanism of Clavatol was also stμdied. The resμlts of 
morphological observation、FCM、mitochondria membrane potential,、Annexin-V、 
ROS detection and Western blotting showed that the compoμnd indμces apoptosis of 
tμmor cells. The exact mechanism of its anti-tμmor activity needed to have fμrther 
stμdy. 
Strain BYY-1 was fermented by optimal mediμm in Submerged fermentation 
manner and Clavatol were gained. The in vivo test showed that the compoμnd has the 
toxicity to moμse with LD50 1000-1250mg/kg, and the anti-tμmor activity inhibited 
mice sarcoma s-180 cell line with ED50 111.87mg/kg. The therapy index was 10.61.  
Oμr stμdy indicated that metabolite Clavatol from strain BYY-1 was worth to be 
researched in-depth. Compoμnd Clavatol had the potentiality to be a new anti-tμmor 
drμg in clinic. 
























































表 1 部分已进入临床前或临床期研究的抗肿瘤活性海洋天然产物 
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HDAC/DNMT Phase I 
Discodermolide 
Discodermia dissolμte    
（sponge） 





（synthetic analogue of 
sponge metabolite） 
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多。相比之下，对海洋真菌的研究进展较缓慢。1945 年，Giμseppe Brotzu 从海水中
分离得到了一株与顶头孢霉相似的真菌，具有抗细菌的活性，这个观察报告通向了











Sansalvamide 是 Fenical 研究小组从 Bahamas 岛的海草 HalodμLe wrightii 表面
分离得到的一株 Fμsariμm 属真菌中分离得到的一个新环肽化合物，见图 1，美国
国家癌症研究所（NCI）测定了其对 60 种细胞株的细胞毒活性，平均 IC50 为 
27.4μg/mL，其对结肠癌细胞株 COLO205 和黑色素瘤细胞株 SK-MEL-2 的 IC50 
分别为 3.5 和 5.9μg/mL，这与 FDA 核准的一些抗肿瘤药物比较，如 mitomycin C
对以上两种细胞的 IC50 为 5.3μg/mL[15，16]，Sansalvamide 表现出高细胞毒活性[14]。 
Olga F. Smetanina 等从海洋真菌 Penicilliμm janthinellμm 中分离出三个新吲哚生
物碱化合物 Shearinines D， E， and F。Shearinines D， E 可诱导人白血病细胞 HL-60
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